
The FDA granted a priority review to acalabrutinib for the treatment of previously untreated adults with mantle cell lymphoma.
The FDA granted a priority review to acalabrutinib for the treatment of previously untreated adults with mantle cell lymphoma.
The FDA approved neoadjuvant nivolumab plus chemo, followed by adjuvant nivolumab for non-small cell lung cancer without EGFR mutations or ALK rearrangements.
Follow-up from the CARTITUDE-4 trial showed that cilta-cel improved survival over standard of care in pretreated myeloma.
Cilta-cel led to high response rates and a promising safety profile in a real-world population of patients with relapsed/refractory myeloma.
Belantamab mafodotin plus KRd had a a manageable safety profile and deep responses in pretreated multiple myeloma.
Older adults with acute myeloid leukemia treated with anthracyclines tended to live longer, but also had more time spent in the hospital compared with those treated with HMAs.
ODAC voted against the use of PD-L1 expression as a predictive biomarker in gastric cancers.
When it comes to cancer-related malnutrition, nurses should look out for more signs than just weight loss.
Oncology nurses and APPs play a role in supporting caregivers while the patient they care for receives a diagnosis and cancer treatment.
Oncology nurses should inform patients about adverse events and the signs of interstitial lung disease before treating their breast cancer with T-DXd.
The agency approved selpercatinib for the treatment of patients with advanced or metastatic, RET-mutant medullary thyroid cancer.
Belantamab plus VRd led to promising outcomes in newly diagnosed transplant-eligible myeloma, study results showed.
An oncology research nurse balances patient care with rigorous data collection, emphasizing communication and collaboration to advance cancer research.
The FDA approved osimertinib for locally advanced, unresectable stage III EGFR-mutated non-small cell lung cancer.
Neoadjuvant immune checkpoint inhibitors plus chemotherapy also improved efficacy outcomes in PD-L1-positive/ERBB2-negative tumors.
Distant relapse-free survival was maintained with non-operative management of pMMR locally advanced rectal cancer.
Chlorhexidine dressings, along with proper patient education, are key in preventing central line-associated blood stream infections in patients with cancer.
A group of advanced practice providers discuss treatment options for a woman with newly diagnosed, transplant-ineligible multiple myeloma.
Olaparib after surgery resulted in durable response rates in patients with high-risk biochemically recurrent prostate cancer with BRCA2 alterations.
Belrestotug plus dostarlimab-gxly improved ORR in patients with previously untreated, unresectable, locally advanced or metastatic, PD-L1–high NSCLC.
Nurses play a crucial role for patients with prostate cancer undergoing radiation treatment, according to a radiation oncology nurse.
Patients with metastatic castration-resistant prostate cancer who received radium-223 prior to docetaxel had better quality of life and tolerability scores than those who received docetaxel first.
A nurse practitioner discusses her role in caring for patients with multiple myeloma, and how advanced practice providers have a unique skillset to offer in cancer care.
Adagrasib outperformed docetaxel in patients with KRAS G12C-mutated non–small cell lung cancer, regardless of baseline brain metastases.
Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF V600–positive melanoma.
Guiding treatment via response predictive subtype could be beneficial for identifying patients with high-risk breast cancer who may respond to Dato-DXd plus durvalumab.
Pembrolizumab led to improved survival over ipilimumab in patients with unresectable advanced melanoma, according to long-term data.
The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who are ineligible for ASCT.
NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma.